---
actionable_items:
- action: potentially
  category: investigation
  full_context: 'we could potentially '
  priority: medium
companies:
- category: unknown
  confidence: medium
  context: Welcome everyone to the AI and Business Podcast. I'm Matthew Damello, Editorial
    Director here at
  name: Business Podcast
  position: 31
- category: unknown
  confidence: medium
  context: come everyone to the AI and Business Podcast. I'm Matthew Damello, Editorial
    Director here at Emerge AI Research. T
  name: Matthew Damello
  position: 53
- category: unknown
  confidence: medium
  context: the AI and Business Podcast. I'm Matthew Damello, Editorial Director here
    at Emerge AI Research. Today's guest is Jung
  name: Editorial Director
  position: 70
- category: unknown
  confidence: medium
  context: . I'm Matthew Damello, Editorial Director here at Emerge AI Research. Today's
    guest is Jung Liu, Director of Data Scie
  name: Emerge AI Research
  position: 97
- category: unknown
  confidence: medium
  context: ctor here at Emerge AI Research. Today's guest is Jung Liu, Director of
    Data Science in AI at Novartis. Jung
  name: Jung Liu
  position: 134
- category: unknown
  confidence: medium
  context: Research. Today's guest is Jung Liu, Director of Data Science in AI at
    Novartis. Jung joins us on today's show
  name: Data Science
  position: 156
- category: unknown
  confidence: medium
  context: ecutive thought leaders, everyone from the CIO of Goldman Sachs to the
    head of AI at Raytheon and AI pioneers lik
  name: Goldman Sachs
  position: 1332
- category: unknown
  confidence: medium
  context: o the head of AI at Raytheon and AI pioneers like Yasha Wabengio. With
    nearly a million annual listeners, AI and B
  name: Yasha Wabengio
  position: 1397
- category: unknown
  confidence: medium
  context: eve you can help other leaders move the needle on AI ROI, visit Emerge.com
    and fill out our Thought Leader
  name: AI ROI
  position: 1865
- category: unknown
  confidence: medium
  context: edle on AI ROI, visit Emerge.com and fill out our Thought Leaders submission
    form. That's Emerge.com and click on b
  name: Thought Leaders
  position: 1907
- category: unknown
  confidence: medium
  context: ne. Again, that's emerj.com/expertone. Hey folks, Steven Johnson here,
    co-founder of Notebook LM. As an author, I'
  name: Steven Johnson
  position: 2159
- category: unknown
  confidence: medium
  context: ne. Hey folks, Steven Johnson here, co-founder of Notebook LM. As an author,
    I've always been obsessed with how
  name: Notebook LM
  position: 2194
- category: tech
  confidence: high
  context: and helping you brainstorm. Try it at notebooklm.google.com. Without further
    ado, here's our conversation
  name: Google
  position: 2559
- category: unknown
  confidence: medium
  context: Without further ado, here's our conversation with Zhong Liu. Dr. Liu, thank
    you so much for being with us onc
  name: Zhong Liu
  position: 2621
- category: unknown
  confidence: medium
  context: many, many different aspects, R&D in healthcare. If I can jump in just
    right there very quickly, just t
  name: If I
  position: 5301
- category: unknown
  confidence: medium
  context: lking about generic AI versus the domain-specific Gen AI. When we delve
    into those domain-specific use cas
  name: Gen AI
  position: 7024
- category: unknown
  confidence: medium
  context: sults, you know, as for the healthcare companies. So I think it's a combination,
    it's a hybrid method, r
  name: So I
  position: 17986
- category: unknown
  confidence: medium
  context: s to have some awareness of this history as well. And I think this episode
    and everything we've described
  name: And I
  position: 24102
- category: ai_media_and_research
  confidence: high
  context: The organization hosting the 'AI and Business Podcast' and featuring executive
    thought leaders on AI adoption.
  name: Emerge AI Research
  source: llm_enhanced
- category: ai_user_life_sciences
  confidence: high
  context: The company where the guest, Jung Liu, is the Director of Data Science
    in AI, focusing on applying generative AI in R&D and clinical workflows.
  name: Novartis
  source: llm_enhanced
- category: ai_user_enterprise
  confidence: medium
  context: Mentioned as an example of a company whose CIO has been featured on the
    podcast, indicating enterprise AI adoption.
  name: Goldman Sachs
  source: llm_enhanced
- category: ai_user_enterprise
  confidence: medium
  context: Mentioned as an example of a company whose head of AI has been featured
    on the podcast, indicating enterprise AI adoption.
  name: Raytheon
  source: llm_enhanced
- category: ai_application
  confidence: high
  context: An AI-first tool built by Steven Johnson for organizing ideas and making
    connections by uploading documents.
  name: Notebook LM
  source: llm_enhanced
- category: ai_infrastructure
  confidence: high
  context: Mentioned as the originator of the transformer architecture that underpins
    modern LLMs and foundation models.
  name: Google
  source: llm_enhanced
- category: ai_application
  confidence: high
  context: The specific URL provided for the Notebook LM tool, tying it directly to
    Google's ecosystem.
  name: NotebookLM.google.com
  source: llm_enhanced
- category: ai_consulting_and_research
  confidence: high
  context: Mentioned for conducting a survey on generative AI investment and scaling
    in the life sciences sector.
  name: Deloitte
  source: llm_enhanced
- category: ai_application
  confidence: high
  context: Mentioned as a reference point for the explosion of LLMs, contrasting with
    earlier models like BERT.
  name: ChatGPT
  source: llm_enhanced
- category: ai_research
  confidence: high
  context: Mentioned as an earlier language model (pre-ChatGPT) based on the decoder
    part of the transformer architecture, used for information extraction.
  name: BERT
  source: llm_enhanced
- category: ai_application
  confidence: high
  context: Referenced generally (GPT-like models) in the context of leveraging the
    decoding part of the transformer architecture to generate new data types (like
    sequences/graphs for molecules).
  name: GPT
  source: llm_enhanced
- category: ai_research
  confidence: high
  context: Mentioned as being good at building foundation models and publishing results.
  name: academic (institutions/researchers)
  source: llm_enhanced
- category: big_tech
  confidence: high
  context: General source of open public architectures that can be leveraged.
  name: tech companies
  source: llm_enhanced
- category: industry_user
  confidence: high
  context: Entities that may leverage published models or build proprietary versions.
  name: healthcare companies
  source: llm_enhanced
date: 2025-10-21 06:00:00 +0000
duration: 31
has_transcript: false
insights:
- actionable: true
  confidence: medium
  extracted: align, you know, between different parties, like scientists, basic scientists,
    or AI modelers, AI professionals, and also leadership teams, AI adoption, etc
  text: we should align, you know, between different parties, like scientists, basic
    scientists, or AI modelers, AI professionals, and also leadership teams, AI adoption,
    etc.
  type: recommendation
layout: episode
llm_enhanced: true
original_url: https://traffic.libsyn.com/secure/techemergence/Business_-_10.21.25_-_Xiong_Liu.mp3?dest-id=151434
processing_date: 2025-10-21 09:48:36 +0000
quotes:
- length: 205
  relevance_score: 8
  text: So you can use this kind of advanced embedding-like features to improve the
    prediction accuracy of your machine learning but now the GPT they also leverage
    the decoding part of the transformer architecture
  topics: []
- length: 244
  relevance_score: 6
  text: So we have witnessed from the early years the machine learning technologies,
    by the supervised learning, unsupervised learning, and then we move to the deep
    learning techniques like convolutional neural networks, RNNs, and graph neural
    networks
  topics: []
- length: 238
  relevance_score: 6
  text: So the benefit is that even if you have very small data for your own machine
    learning tasks, you can leverage those foundation models because they already
    capture some relevant information, although it may not be specifically to your
    data
  topics: []
- length: 156
  relevance_score: 4
  text: Jung joins us on today's show to explore how generative AI and large language
    models are revolutionizing R&D and clinical workflows throughout life sciences
  topics: []
- length: 289
  relevance_score: 4
  text: Together, we break down the shift from traditional task-based machine learning
    to foundational models that leverage massive data repositories, enabling teams
    to accelerate molecule design, digital twin creation, and protocol optimization
    through deeper automation and improved data quality
  topics: []
- length: 238
  relevance_score: 4
  text: Our conversation also highlights practical challenges in workflow, including
    building domain-specific benchmarks, enabling tighter alignment between scientists
    and AI teams, and adopting new evaluation standards for AI-driven research ROI
  topics:
  - valuation
- length: 152
  relevance_score: 4
  text: But first, are you driving AI transformation at your organization, or maybe
    you're guiding critical decisions on AI investments, strategy, or deployment
  topics:
  - investment
- length: 134
  relevance_score: 4
  text: Obviously, this is a developing story from even a few years ago where we saw
    the explosion of LLMs and generative AI across industries
  topics: []
- length: 233
  relevance_score: 4
  text: So the difference is that previously when we do machine learning, we just
    collect our own data, we label the data, and then apply algorithms to train models
    so that we can get a working model to predict the outputs for the new inputs
  topics: []
- length: 99
  relevance_score: 4
  text: But now people have been developing these new paradigms, which is along with
    LLMs foundation models
  topics: []
- length: 159
  relevance_score: 4
  text: So we are familiar with LLMs, they trained based on all the human corpus,
    all the human languages you can imagine, all field of settings, large language
    models
  topics: []
- length: 101
  relevance_score: 4
  text: Fine-tuning meaning yes, we take the foundation models but we can still take
    the data you have, right
  topics: []
- length: 95
  relevance_score: 4
  text: It doesn't mean we retrain the whole, you know, the foundation model, large
    language model, etc
  topics: []
- length: 219
  relevance_score: 4
  text: Maybe we can give some more detailed examples about how GenAI and the foundation
    models work and then we can delve into, you know, the development, right, how
    we build up and, you know, put those models into work, right
  topics: []
- length: 229
  relevance_score: 4
  text: I just give some examples about using foundation models, GenAI to generate
    new cell types and gene expressions so that we can do all kinds of in silico,
    you know, treatment methods to see, to observe the predicted phenotypes, etc
  topics: []
- length: 142
  relevance_score: 4
  text: They could all fit into those kind of transformer architecture to let you
    learn the hidden embedding signatures of those molecules, atoms, etc
  topics: []
- length: 283
  relevance_score: 4
  text: And then this text knowledge about not just AI, computer science, but also
    the knowledge about the data themselves, although the goal of the foundation model
    is, it's tried to, you know, leverage all the available data, minimizing, you
    know, the specifics, you know, of specific data
  topics: []
- length: 152
  relevance_score: 4
  text: And we see this built in, it's an advantage that natural language processing
    as a domain became one of the first gigantic generative AI use cases, right
  topics: []
- length: 70
  relevance_score: 3
  text: So we can use the data you have to train to fine-tune the model, right
  topics: []
- length: 105
  relevance_score: 3
  text: So that is based on the breakthrough of the transformer architecture that
    Google proposed a long time ago
  topics: []
- impact_reason: Defines the core difference between traditional ML (task-specific,
    labeled data) and the foundation model approach (leveraging massive, domain-wide
    data for large-scale pre-training).
  relevance_score: 10
  source: llm_enhanced
  text: Previously when we do machine learning, we just collect our own data, we label
    the data, and then apply algorithms to train models... But now people have been
    developing these new paradigms, which is along with LLMs foundation models. So
    the idea is that yes, you still care about the specific data you are working on,
    but at the same time, we want to collect all the available data, relevant data,
    or irrelevant data, but as long as they fall into the same domain, and fill those
    data into those transformer architectures to build a much large-scale pre-trained
    models.
  topic: technical insight
- impact_reason: Provides a concrete example of foundation models transforming R&D
    in life sciences by leveraging public domain data (like cell atlases) to inform
    specific, proprietary tasks (disease pathway study).
  relevance_score: 10
  source: llm_enhanced
  text: When we delve into those domain-specific use cases, we probably can better
    understand the benefit of foundation models. So for example, when we study the
    disease pathways and identify new targets for specific indications... But now
    with foundation models, it has a lot of pre-trained models based on publicly available
    molecular data. So for example, cell atlases, etc.
  topic: industry application (Life Sciences)
- impact_reason: 'A powerful conceptual link: framing genetics/biological code as
    a language suitable for LLM processing, suggesting massive efficiency gains in
    early drug development.'
  relevance_score: 10
  source: llm_enhanced
  text: genetics are just code, they're just a language so we can build a large language
    model to have kind of the same functionality or be able to test a lot of the,
    you know, genetic functions of a compound as an example to maybe take away some
    of the larger heavy work of much of across the drug development process.
  topic: predictions/industry application
- impact_reason: 'Highlights a cutting-edge application: using GenAI to synthesize
    biological data (cell types, gene expressions) for *in silico* testing, accelerating
    preclinical research.'
  relevance_score: 10
  source: llm_enhanced
  text: People have been already applying those models. I just give some examples
    about using foundation models, GenAI to generate new cell types and gene expressions
    so that we can do all kinds of in silico, you know, treatment methods to see,
    to observe the predicted phenotypes, etc.
  topic: industry application (R&D)
- impact_reason: Clearly explains the shift from representation learning (BERT) to
    generative capabilities (GPT) enabled by leveraging the decoder stack.
  relevance_score: 10
  source: llm_enhanced
  text: but now the GPT they also leverage the decoding part of the transformer architecture.
    So meaning they are now able to generate new types of data.
  topic: technical
- impact_reason: Crucial insight into conditional generation in scientific domains,
    moving beyond simple generation to constrained, goal-oriented design (e.g., optimizing
    for toxicity and solubility simultaneously).
  relevance_score: 10
  source: llm_enhanced
  text: And really, yeah, additionally, also based on your constraints, your requirements,
    your domain-specific knowledge. So for example, you can generate many different
    types of new molecules, but you can add constraints like have, you know, better
    toxicity, solubility, etc. It can allow you to, you know, do that simultaneously.
  topic: technical
- impact_reason: 'A profound limitation: AI model potential is currently constrained
    by the speed and feasibility of experimental data generation (the ''experimental
    side'').'
  relevance_score: 10
  source: llm_enhanced
  text: I mean, that is potentially possible. But unfortunately, to get those, you
    know, single-cell RNA-seq data, all those kind of more, you know, experiment-driven
    data, probably we're not exactly there yet, because, you know, we still rely on
    those traditional biotechnology methods to collect those data through experiments
    on cell lines, on human tissues, etc. So, there's, you know, where AI, the architecture,
    the concept there, but the, sometimes we are limited by the, you know, experimental
    side.
  topic: limitations
- impact_reason: Articulates the heightened danger of hallucination in scientific
    domains where validation requires expensive, slow physical experiments rather
    than instant code/text checks.
  relevance_score: 10
  source: llm_enhanced
  text: a way of phenomenon is about hallucination, right? So, when those models,
    AI models, they generate new outputs, they probably seemingly like answers. But
    if you delve into that... But when it goes to the bio-medical, biochemistry, etc.
    For example, it generates a new set of genes, a new molecule, is this something
    that you cannot be answered or validated instantly?
  topic: safety
- impact_reason: Clearly outlines the historical evolution of AI/ML, highlighting
    the current 'paradigm shift' to foundation models, which is crucial context for
    understanding modern AI strategy.
  relevance_score: 9
  source: llm_enhanced
  text: we have witnessed from the early years the machine learning technologies,
    by the supervised learning, unsupervised learning, and then we move to the deep
    learning techniques like convolutional neural networks, RNNs, and graph neural
    networks. And more recently, we have a paradigm shift into those language models,
    foundation models.
  topic: technical trends
- impact_reason: 'Explains the key value proposition of foundation models: enabling
    performance on tasks with limited proprietary data by transferring knowledge from
    broad pre-training.'
  relevance_score: 9
  source: llm_enhanced
  text: The benefit is that even if you have very small data for your own machine
    learning tasks, you can leverage those foundation models because they already
    capture some relevant information, although it may not be specifically to your
    data. So that's why they are called foundation models. They could be useful for
    many downstream tasks.
  topic: technical insight
- impact_reason: Offers a precise, accessible definition of fine-tuning in the context
    of foundation models, clarifying that it involves adjusting weights rather than
    full retraining.
  relevance_score: 9
  source: llm_enhanced
  text: Fine-tuning meaning yes, we take the foundation models but we can still take
    the data you have, right? So we can use the data you have to train to fine-tune
    the model, right? It's called fine-tune. It doesn't mean we retrain the whole,
    you know, the foundation model, large language model, etc. We just adjust the
    weights based on the data you have so that it can better be personalized for your
    problems.
  topic: technical insight
- impact_reason: Provides a key industry metric illustrating the significant 'AI implementation
    gap' or 'pilot purgatory' challenge facing life sciences.
  relevance_score: 9
  source: llm_enhanced
  text: Deloitte survey notes that while 73% of life sciences leaders are investing
    in generative AI initiatives, fewer than 20% have successfully scaled these technologies
    beyond pilot projects.
  topic: business challenge
- impact_reason: Lists specific, practical challenges organizations face when operationalizing
    AI in scientific workflows (benchmarking, collaboration, ROI measurement).
  relevance_score: 9
  source: llm_enhanced
  text: building domain-specific benchmarks, enabling tighter alignment between scientists
    and AI teams, and adopting new evaluation standards for AI-driven research ROI.
  topic: practical challenges
- impact_reason: Articulates the concept of using population-level foundation models
    against individual patient data to create a functional 'digital twin' for trial
    management or personalized medicine.
  relevance_score: 9
  source: llm_enhanced
  text: we can take these models that really know this genetic code very well for
    everyone and then the folks, the professionals running the clinical trials can
    run that foundational model based on what they're seeing with this specific patient
    and that kind of acts like the digital twin.
  topic: industry application/prediction
- impact_reason: 'Highlights the core value proposition of using foundation models
    in drug discovery: focusing human effort on high-potential novel targets rather
    than broad screening.'
  relevance_score: 9
  source: llm_enhanced
  text: So that way can allow us to better focus on discovering, you know, novel targets,
    novel gene pathways, etc.
  topic: predictions
- impact_reason: Illustrates the concept of applying large-scale pre-training techniques
    (like those used for language) to structured biological/chemical data (SMILES,
    graphs).
  relevance_score: 9
  source: llm_enhanced
  text: So all those information publicly available data are from different databases.
    They could all fit into those kind of transformer architecture to let you learn
    the hidden embedding signatures of those molecules, atoms, etc.
  topic: technical
- impact_reason: Emphasizes the indispensable role of domain experts in data curation,
    model guidance, and, critically, benchmarking foundation models.
  relevance_score: 9
  source: llm_enhanced
  text: But, you know, we still need the domain knowledge people, you know, people
    have those kind of expertise to guide the, you know, the selection of the data
    and also more importantly, then these models are, you build, now how do we benchmark
    with them?
  topic: strategy
- impact_reason: 'Proposes the necessary solution for navigating the proliferation
    of specialized models: evaluation must be driven by both domain expertise and
    AI metrics.'
  relevance_score: 9
  source: llm_enhanced
  text: So, I think this domain-driven, domain and AI-driven evaluation is key here,
    because there could be so many versions of found data models.
  topic: strategy
- impact_reason: Identifies organizational alignment and communication between disparate
    groups (scientists, modelers, leadership) as a critical barrier to effective AI
    adoption.
  relevance_score: 9
  source: llm_enhanced
  text: So, there's a lot of cultural organizational issue. I see the key that really
    we should align, you know, between different parties, like scientists, basic scientists,
    or AI modelers, AI professionals, and also leadership teams, AI adoption, etc.
  topic: business
- impact_reason: Describes a strategic shift in data managementâ€”centralizing vast,
    diverse data first, then applying advanced algorithms, moving beyond simple document
    processing to strategic automation.
  relevance_score: 8
  source: llm_enhanced
  text: We're seeing a new model where you have a large data repository where everything
    goes, all data is great data. We'll be discriminating about it later, discriminating
    about it later, but from that data repository we can drive more advanced algorithms
    to help with strategic tasks across the entire organization that need that kind
    of whole-scale approach.
  topic: strategy
- impact_reason: Poses a critical business/strategy question regarding the build vs.
    buy decision for foundation models, especially in regulated or specialized domains
    like healthcare.
  relevance_score: 8
  source: llm_enhanced
  text: I'm just curious for these foundational models, is it more often that the
    organizations themselves are developing them or is there a third-party more robust
    market?
  topic: business strategy
- impact_reason: Reiterates that the underlying technical commonality across diverse
    foundation models (text, image, molecular) is the Transformer architecture.
  relevance_score: 8
  source: llm_enhanced
  text: all those models, you know, essentially they have the same, I mean, by nature,
    they have the same setup. So that is based on the breakthrough of the transformer
    architecture that Google proposed a long time ago.
  topic: technical foundation
- impact_reason: Summarizes the core promised benefits of GenAI adoption in life sciences
    R&D.
  relevance_score: 8
  source: llm_enhanced
  text: enabling teams to accelerate molecule design, digital twin creation, and protocol
    optimization through deeper automation and improved data quality.
  topic: business impact
- impact_reason: Provides a concise technical distinction between BERT-style models
    (encoder-only, good for representation/embeddings) and generative models.
  relevance_score: 8
  source: llm_enhanced
  text: So the difference is that the previously BERT architecture they use the decoder
    part of the transformer. So you can think it's as a very good representation model.
  topic: technical
- impact_reason: 'A key strategic takeaway for implementing AI in specialized fields:
    success requires mandatory, deep collaboration between AI/CS experts and domain
    scientists.'
  relevance_score: 8
  source: llm_enhanced
  text: So, yeah, so it's basically a cross-discipline collaboration, whether in house
    or externally, yeah.
  topic: strategy
- impact_reason: Identifies a structural advantage for language-like data domains
    (like genetics) in leveraging early GenAI breakthroughs compared to other scientific
    modalities.
  relevance_score: 8
  source: llm_enhanced
  text: it's an advantage that natural language processing as a domain became one
    of the first gigantic generative AI use cases, right? That builds in certain advantage
    to genetics, which is more language-based than anything else versus, you know,
    other domains of health and life sciences, the services involved.
  topic: predictions
- impact_reason: 'Actionable advice: rigorous, informed benchmarking is essential
    for model selection in high-stakes applications.'
  relevance_score: 8
  source: llm_enhanced
  text: So, it's quite important that we have to do those benchmarking and select
    models accordingly.
  topic: business
- impact_reason: 'Highlights the ''digestibility'' problem: technical model capabilities
    must be translated and validated by subject matter experts for organizational
    uptake.'
  relevance_score: 8
  source: llm_enhanced
  text: how do we digest the models, the capabilities? And again, we have to plug
    in, you know, the right scientists to help us together validate those.
  topic: strategy
- impact_reason: Strategic insight that AI adoption in life sciences will be a hybrid
    approach, not a complete replacement of existing paradigms, requiring SMEs to
    understand both.
  relevance_score: 8
  source: llm_enhanced
  text: It behooves them to kind of have some awareness of the new and old paradigm
    that we were talking about before, how both are still present, but how we thought
    that AI would impact life sciences organization or that they'd just be this one
    school way of doing things is not the case.
  topic: strategy
- impact_reason: Indicates that the initial industry framing of 'foundation + bespoke'
    models is evolving, suggesting a more integrated or nuanced deployment strategy
    is emerging.
  relevance_score: 7
  source: llm_enhanced
  text: this was more around 2022, 2023, you know, across industries business leaders
    would always talk about, oh, you'll have these foundational and then bespoke models,
    this is a little bit dated, it's not how, you know, these models necessarily got
    talked about across industries going forward.
  topic: strategy/trends
- impact_reason: 'Reiterates the universal bottleneck in specialized AI: the need
    for high-quality, domain-specific data, even when using massive general architectures.'
  relevance_score: 7
  source: llm_enhanced
  text: So, so let's talk through the, you know, the challenges, you know, of building
    and deploying those models. So, the first thing is about the data challenge, right?
    So, so the foundation models, although they take all kinds of available data,
    but still they require high-quality data.
  topic: business
- impact_reason: Crucial disclaimer indicating the personal, non-corporate nature
    of the insights shared, which often allows for more candid discussion.
  relevance_score: 6
  source: llm_enhanced
  text: Just a quick note for our audience that the views expressed by Jung on today's
    program do not reflect those of Novartis or its leadership.
  topic: context/disclaimer
source: Unknown Source
summary: '## Comprehensive Summary: Building AI-Ready Cultures in Life Sciences R&D


  This 30-minute podcast episode, featuring **Zhong Liu, Director of Data Science
  in AI at Novartis**, focuses on the paradigm shift in Life Sciences R&D driven by
  **Generative AI (GenAI)** and **Foundation Models (FMs)**, and the cultural and
  technical challenges of scaling these technologies beyond pilot projects.


  ### 1. Focus Area

  The discussion centers on the transition from traditional, task-specific Machine
  Learning (ML) to leveraging large-scale Foundation Models in drug discovery, clinical
  workflows, and protocol design. Key themes include the architectural differences
  between older models (like BERT) and generative models (like GPT), the role of massive,
  domain-specific data repositories, and the necessity of building "AI-ready cultures"
  to bridge the gap between AI developers and domain scientists.


  ### 2. Key Technical Insights

  *   **Shift to Foundation Models:** The core technical evolution involves moving
  from training models solely on proprietary, labeled data to utilizing massive, pre-trained
  FMs (built on transformer architectures) that capture broad domain knowledge. This
  allows for effective downstream tasks even with small, specific datasets via **fine-tuning**.

  *   **Generative Capabilities:** Unlike older representation models (like BERT),
  modern generative FMs (like GPT) leverage the decoder part of the transformer, enabling
  them to generate novel outputs, such as new molecular sequences (represented as
  SMILES strings or graphs) constrained by desired properties (e.g., toxicity, solubility).

  *   **Digital Twins Analogy:** Foundational models, when applied to vast, de-identified
  genetic and biological code, can function similarly to digital twins, allowing researchers
  to simulate and test hypotheses *in silico* regarding patient data, disease pathways,
  and compound efficacy before physical experimentation.


  ### 3. Business/Investment Angle

  *   **Scaling Gap:** Despite high investment (73% of life sciences leaders investing
  in GenAI), successful scaling remains low (under 20%), highlighting significant
  implementation hurdles beyond initial experimentation.

  *   **Data Dependency vs. Model Power:** While FMs reduce the reliance on massive
  *labeled* proprietary datasets for every new task, the overall success still hinges
  on the availability of high-quality, comprehensive data (e.g., single-cell RNA-seq)
  to feed and fine-tune these models effectively.

  *   **ROI Evaluation Challenge:** Measuring the Return on Investment (ROI) for AI-driven
  research is complex because outputs (like novel molecules or gene pathways) cannot
  be instantly validated, necessitating the creation of **domain-driven evaluation
  metrics and knowledge-checking benchmarks**.


  ### 4. Notable Companies/People

  *   **Zhong Liu (Novartis):** The guest, providing insights from a major pharmaceutical
  company on practical implementation and cultural alignment.

  *   **Google (Transformer Architecture):** Mentioned as the source of the foundational
  architectural breakthrough enabling modern FMs.

  *   **Deloitte:** Referenced for a recent survey quantifying the gap between GenAI
  investment and successful scaling in life sciences.


  ### 5. Future Implications

  The industry is moving toward a hybrid development model, leveraging publicly available
  FMs while simultaneously building proprietary, domain-specific FMs tailored to complex
  biological systems. Success will depend less on pure algorithmic advancement and
  more on **cross-disciplinary collaboration** and establishing robust, objective
  evaluation standards that integrate biological expertise with AI performance metrics
  to mitigate risks like model hallucination.


  ### 6. Target Audience

  This episode is highly valuable for **Life Sciences R&D Leaders, Chief Data Officers,
  AI/ML Strategy Executives, and Data Science Professionals** working within Pharma
  and Biotech who are tasked with moving GenAI initiatives from pilot phases into
  scalable, impactful workflows.'
tags:
- artificial-intelligence
- generative-ai
- investment
- ai-infrastructure
- startup
- google
title: Building AI-Ready Cultures in Life Sciences R&D - with Xiong Liu of Novartis
topics:
- keywords:
  - ai
  - machine learning
  - deep learning
  - neural networks
  - llm
  - large language model
  mentions: 121
  prominence: 1.0
  topic: artificial intelligence
- keywords:
  - generative ai
  - genai
  - chatgpt
  - gpt
  - claude
  - text generation
  - image generation
  mentions: 13
  prominence: 1.0
  topic: generative ai
- keywords:
  - investment
  - funding
  - valuation
  - ipo
  - acquisition
  mentions: 4
  prominence: 0.4
  topic: investment
- keywords:
  - gpu
  - tensor
  - training
  - inference
  - model deployment
  - vector database
  mentions: 1
  prominence: 0.1
  topic: ai infrastructure
- keywords:
  - startup
  - entrepreneur
  - founder
  - venture
  mentions: 1
  prominence: 0.1
  topic: startup
---

<!-- Episode automatically generated from analysis data -->
<!-- Processing completed: 2025-10-21 09:48:36 UTC -->
